Live Breaking News & Updates on International Prognostic Scoring System

Stay updated with breaking news from International prognostic scoring system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males

Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men. ....

Moffitt Cancer Center , International Prognostic Scoring System , World Health Organization , Moffitt Cancer , Revised International Prognostic Scoring System , Very High Risk Prognosis ,

Agios Pharma (AGIO) Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946

Agios Pharma (AGIO) Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Sarah Gheuens , Agios Pharmaceuticals Inc , American Society Of Hematology , International Prognostic Scoring System , Agios Pharmaceuticals , Design The , Revised International Prognostic Scoring System , American Society , Annual Meeting ,

Higher Leptin Levels, Body Fat Linked to MDS in Study

The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the relationship between LEP and myelodysplastic syndrome (MDS). ....

United Kingdom , University Of Cear , World Health Organization , International Prognostic Scoring System , British Journal , Federal University ,

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents. ....

United States , Markku Jalkanen , Faron Pharmaceuticals , Faron Pharmaceuticals Ltd , International Prognostic Scoring System , Bayesian Optimal Interval , Rr Aml , Relapsed Or Refractory Acute Myeloid Leukemia , Hypomethylating Agents , Phase 1 2 Bexmab Study Nct05428969 ,